ClinicalTrials.gg
Not yet recruitingNCT05239650Updated May 3, 2022

Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07+HLX10 +mFOLFOX6 or HLX07 Monotherapy in Patients With mCRC

A Phase 2 interventional study of HLX07 and HLX10 in CRC, sponsored by Shanghai Henlius Biotech. Not yet recruiting. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-05-03.

Sponsored by Shanghai Henlius Biotech (part of Fosun Pharma) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Oct 2025, 1 year 1 month ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
50
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This is An Open-label, Multicenter, Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07 (Recombinant Humanized Anti-EGFR Monoclonal Antibody Injection) + HLX10 (Recombinant Humanized Anti-PD-1 Monoclonal Antibody Injection) + mFOLFOX6 or HLX07 Monotherapy in Patients with Metastatic Colorectal Cancer.

02

Conditions studied

  • CRC
03

In context

Lead sponsor

Shanghai Henlius Biotech is the lead sponsor of 132 studies on the registry; 56 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age>=18Y and ≤75Y
  • Good Organ Function
  • Expected survival time ≥ 3 months
  • mCRC that have been diagnosed histologically
  • KRAS/NRAS/BRAF WT verified by PCR or NGS of tumor tissue
  • score 0-1;

Exclusion criteria

Exclusion Criteria:

  • infection
  • Active clinical severe infection;
  • A history of other within two years, except for cured carcinoma in situ of the cervix or basal cell carcinoma of the skin.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    A:1L treatment

    HLX07 \* 1000 mg+HLX10\* 200mg +mFOLFOX6, IV, Q2W

    Drug: HLX07 · Drug: HLX10 · Drug: mFOLFOX6

  • Experimental
    B:≥2L treatment

    HLX07 \*1000 mg monotherapy,IV, Q2W

    Drug: HLX07

Interventions

  • DrugHLX07

    1000mg

  • DrugHLX10

    200mg

  • DrugmFOLFOX6

    OXA:85 mg/m2;LV:400 mg/m2;5-FU:400 mg/m2

06

What researchers measure

Primary outcomes

  1. ORR

    Objective response rate (assessed by investigator per RECIST V1.1)

    Time frame: up to 3 years

  2. PFS

    Progression-free survival (PFS) (assessed by the investigator per RECIST v1.1 )

    Time frame: : from the first dose until firstly confirmed and recorded disease progression or death (whichever occurs earlier),up to 3 years

Secondary outcomes

  1. OS

    Overall Survival

    Time frame: up to 5 years

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jul 2022; primary completion for Oct 2025, 39 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 7, 2022
First posted
Feb 15, 2022
StartEst.
Jul 15, 2022
Primary completionEst.
Oct 15, 2025
CompletionEst.
Oct 15, 2026
Last update
May 3, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 3, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05239650
Responsible party
Sponsor
First posted
Feb 15, 2022
Start date
Jul 15, 2022 (estimated)
Primary completion
Oct 15, 2025 (estimated)
Completion
Oct 15, 2026 (estimated)
Last update
May 3, 2022

Study contacts

Peng Junjie
Contact
junjiepeng67@163.com
: 86021-64175590
Peng Junjie
principal investigator · Fudan University Affiliated Oncology Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HLX07

Start the discussion